Diagnoses of depression and anxiety versus current symptoms and quality of life in multiple sclerosis

International Journal of MS Care

Volumn 20, Issue 2, 2018, Pages 76-84

  Marrie, Ruth Ann ^a,h   Patten, Scott B ^b,j   Berrigan, Lindsay I ^c,d   Tremlett, Helen ^e   Wolfson, Christina ^f   Warren, Sharon ^g   Leung, Stella ^a,h   Fiest, Kirsten M ^a   McKay, Kyla A ^e   Fisk, John D ^d,i   Blanchard, James ^h   Caetano, Patricia ^h   Elliott, Lawrence ^h   Yu, Bo Nancy ^h   Bhan, Virender ⁱ   Profetto McGrath, Joanne ^g   Svenson, Larry ^g   Jette, Nathalie ^j   Zhu, Bin ^f   Wang, Yan ⁱ   Hall, Nicholas ^h   Zhu, Feng ^e   Kingwell, Elaine ^e   Stadnyk, Karen ⁱ   more..

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ST FRANCIS XAVIER UNIVERSITY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85045086313     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2016-110     Document Type: Article

References (43)

1. Marrie R, Reider N, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21:305-317
2. Marrie RA, Elliott L, Marriott J, Cossoy M, Tennakoon A, Yu N. Comorbidity increases the risk of hospitalizations in multiple sclerosis. Neurology. 2015;84:350-358
3. Mohr DC, Goodkin DE, Likosky W, Gatto N, Baumann KA, Rudick RA. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54:531-533
4. Marrie RA, Elliott L, Marriott J, et al. Effect of comorbidity on mortality in multiple sclerosis. Neurology. 2015;85:240-247
5. Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86:1287-1295
6. Watson DE, Heppner P, Roos NP, Reid RJ, Katz A. Population-based use of mental health services and patterns of delivery among family physicians, 1992 to 2001. Can J Psychiatry. 2005;50:398-406
7. Honarmand K, Feinstein A. Validation of the Hospital Anxiety and Depression Scale for use with multiple sclerosis patients. Mult Scler. 2009;15:1518-1524
8. Hermann B, Vickrey B, Hays RD, et al. A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res. 1996;25:113-118
9. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler. 2001;7:340-344
10. Bulloch A, Williams J, Lavorato D, Patten S. Recurrence of major depressive episodes is strongly dependent on the number of previous episodes. Depress Anxiety. 2014;31:72-76
11. Rohde P, Lewinsohn PM, Seeley JR. Are people changed by the experience of having an episode of depression? a further test of the scar hypothesis. J Abnorm Psychol. 1990;99:264-271
12. Zeiss AM, Lewinsohn PM. Enduring deficits after remissions of depression: a test of the scar hypothesis. Behav Res Ther. 1988;26:151-158
13. Berrigan LI, Fisk JD, Patten SB, et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016;86:1417-1424
14. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33: 1444-1452
16. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010;35:83-90
17. Centers for Disease Control and Prevention. Behavioral Risk Factor Surveillance System Survey Questionnaire. Atlanta, GA: US Department of Health and Human Services; 1995
18. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry. 2005;76:58-63
19. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54
20. Kuspinar A, Mayo NE. A review of the psychometric properties of generic utility measures in multiple sclerosis. PharmacoEconomics. 2014;32:759-773
21. Fisk JD, Doble SE. Construction and validation of a fatigue impact scale for daily administration (D-FIS). Qual Life Res. 2002;11:263
22. Benito-Leon J, Martinez-Martin P, Frades B, et al. Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). Mult Scler. 2007;13:645-651
23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370
24. British Columbia Ministry of Health [creator]. Discharge Abstract Database (Hospital Separations): 2012. http://www.popdata.bc.ca/data/internal/health/dad. Accessed April 1, 2015
25. British Columbia Ministry of Health [creator]. Medical Services Plan (MSP): 2012. http://www.popdata.bc.ca/data/internal/health/msp. Accessed April 1, 2015
26. British Columbia Ministry of Health [creator]. Consolidation File (MSP Registration & Premium Billing): 2012. http://www.popdata.bc.ca/data/internal/population/consolidationfile. Accessed April 1, 2015
27. Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol. 2013;13:16
28. Marrie RA, Fisk JD, Stadnyk KJ, et al. Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. Chronic Dis Inj Can. 2014;34:145-153
29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174
30. Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012;125: 180-186
31. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003;56:221-229
32. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 2006;253:219-223
33. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and under-treated. Mult Scler. 2009;15:385-392
34. Raissi A, Bulloch AG, Fiest KM, McDonald K, Jette N, Patten SB. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int J MS Care. 2015;17:292-300
35. Koch MW, Patten S, Berzins S, et al. Depression in multiple sclerosis: a long-term longitudinal study. Mult Scler. 2015;21:76-82
36. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13:67-72
37. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15:141-155
38. Feng Y, Bernier J, McIntosh C, Orpana H. Validation of disability categories derived from Health Utilities Index Mark 3 scores. Health Reports. 2009;20:43-50
39. Mitchell AJ, Benito-León J, González J-MM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4: 556-566
40. Wang JL, Reimer MA, Metz LM, Patten SB. Major depression and quality of life in individuals with multiple sclerosis. Int J Psychiatry Med. 2000;30:309-317
41. West SL, Richter A, Melfi CA, McNutt M, Nennstiel ME, Mauskopf JA. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol. 2000;53:823-831
42. Kisely S, Lin E, Lesage A, et al. Use of administrative data for the surveillance of mental disorders in 5 provinces. Can J Psychiatry. 2009;54:571-575
43. McKay KA, Tremlett H, Zhu F, Kastrukoff L, Marrie RA, Kingwell E. A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. Eur J Neurol. 2016;23: 1093-1100